1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Eris Lifesciences Limited

Eris Lifesciences Limited

ERIS.NS
Eris Lifesciences LimitedIN flagNational Stock Exchange of India
1,449.40
INR
+18.30
- -
200.84BMarket Cap

Total Valuation

Eris Lifesciences Limited carries a market capitalization of 200.84B, placing it among publicly traded companies globally. Its enterprise value stands at 199.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap200.84B
Enterprise Value199.64B

Share Statistics

Eris Lifesciences Limited currently has 138.54M shares outstanding.

Shares Outstanding138.54M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Eris Lifesciences Limited trades at a trailing price-to-earnings ratio of 28.55. The price-to-sales ratio is 5.68, and the price-to-book ratio stands at 1,277.18.

PE Ratio28.55
PS Ratio5.68
PB Ratio1,277.18
P/TBV Ratio-30.31
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Eris Lifesciences Limited trades at an EV/EBITDA multiple of 23.75 and an EV/FCF ratio of 102.18. The EV/Sales ratio of 6.41 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.75 provides insight into valuation relative to core operating earnings.

EV / Sales6.41
EV / EBITDA23.75
EV / EBIT23.75
EV / FCF102.18

Financial Position

Eris Lifesciences Limited maintains a current ratio of 0.74, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.54, indicating elevated leverage, while an interest coverage ratio of 4.36 demonstrates adequate ability to service its debt obligations.

Current Ratio0.74
Quick Ratio0.04
Debt / Equity60.54
Debt / EBITDA2.81
Interest Coverage4.36

Financial Efficiency

Eris Lifesciences Limited posts a return on equity of 43.93 and a return on invested capital of 9.94.

Return on Equity (ROE)43.93
Return on Assets (ROA)8.61
Return on Invested Capital (ROIC)9.94
Return on Capital Employed (ROCE)15.32
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.06

Taxes

Over the trailing twelve months, Eris Lifesciences Limited has paid -89.70M in income taxes, reflecting an effective tax rate of 69.60.

Income Tax-89.70M
Effective Tax Rate69.60

Stock Price Statistics

Eris Lifesciences Limited's stock has declined approximately -16.41292% over the past 52 weeks. The 50-day moving average sits at 1,385.72, while the 200-day moving average is 1,459.66.

Beta (5Y)N/A
52-Week Price Change-16.41292%
50-Day Moving Average1,385.72
200-Day Moving Average1,459.66
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Eris Lifesciences Limited generated 31.15B in revenue and converted that into 6.20B in net income, yielding earnings per share of 47.43. EBITDA reached 8.41B, while operating income came in at 8.41B.

Revenue31.15B
Gross Profit23.19B
Operating Income8.41B
Pretax Income6.39B
Net Income6.20B
EBITDA8.41B
EBIT8.41B
Earnings Per Share (EPS)47.43

Balance Sheet

Eris Lifesciences Limited holds 763.80M in cash and equivalents against 23.59B in total debt, resulting in a net debt position of 22.55B. Total book value stands at 138.50M, with working capital of -5.37B providing operational flexibility.

Cash & Cash Equivalents763.80M
Total Debt23.59B
Net Debt22.55B
Equity (Book Value)138.50M
Book Value Per Share1.02
Working Capital-5.37B

Margins

Eris Lifesciences Limited operates with a gross margin of 74.46, reflecting its pricing power and cost economics. The operating margin of 26.99 and net profit margin of 19.89 provide insight into operational efficiency.

Gross Margin74.46
Operating Margin26.99
Pretax Margin20.50
Profit Margin19.89
EBITDA Margin26.99

Scores

Eris Lifesciences Limited posts an Altman Z-Score of 4.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.88